Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 91 entries
Sorted by: Best Match Show Resources per page
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.

Diabetes & metabolism journal

Kim YA, Yoo WS, Hong ES, Ku EJ, Park KS, Lim S, Cho YM, Park KS, Jang HC, Choi SH.
PMID: 26616595
Diabetes Metab J. 2015 Dec;39(6):489-97. doi: 10.4093/dmj.2015.39.6.489. Epub 2015 Nov 27.

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitor add-on therapy is a new option for patients with inadequately controlled type 2 diabetes who are taking combined metformin and sulfonylurea (SU). We evaluated the efficacy and safety of this triple therapy and the...

Cite
Kim YA, Yoo WS, Hong ES, et al. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. Diabetes Metab J. 2015;39(6):489-97doi: 10.4093/dmj.2015.39.6.489.
Kim, Y. A., Yoo, W. S., Hong, E. S., Ku, E. J., Park, K. S., Lim, S., Cho, Y. M., Park, K. S., Jang, H. C., & Choi, S. H. (2015). Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. Diabetes & metabolism journal, 39(6), 489-97. https://doi.org/10.4093/dmj.2015.39.6.489
Kim, Ye An, et al. "Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin." Diabetes & metabolism journal vol. 39,6 (2015): 489-97. doi: https://doi.org/10.4093/dmj.2015.39.6.489
Kim YA, Yoo WS, Hong ES, Ku EJ, Park KS, Lim S, Cho YM, Park KS, Jang HC, Choi SH. Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin. Diabetes Metab J. 2015 Dec;39(6):489-97. doi: 10.4093/dmj.2015.39.6.489. Epub 2015 Nov 27. PMID: 26616595; PMCID: PMC4696985.
Copy Download .nbib Format: NLM
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

The review of diabetic studies : RDS

Gallwitz B.
PMID: 17491680
Rev Diabet Stud. 2005;2(2):61-9. doi: 10.1900/RDS.2005.2.61. Epub 2005 Aug 10.

Orally ingested glucose leads to a greater insulin response compared to intravenously administered glucose leading to identical postprandial plasma glucose excursions, a phenomenon referred to as the "incretin effect". The incretin effect comprises up to 60% of the postprandial...

Cite
Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud. 2005;2(2):61-9doi: 10.1900/RDS.2005.2.61.
Gallwitz, B. (2005). New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. The review of diabetic studies : RDS, 2(2), 61-9. https://doi.org/10.1900/RDS.2005.2.61
Gallwitz, Baptist. "New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins." The review of diabetic studies : RDS vol. 2,2 (2005): 61-9. doi: https://doi.org/10.1900/RDS.2005.2.61
Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud. 2005;2(2):61-9. doi: 10.1900/RDS.2005.2.61. Epub 2005 Aug 10. PMID: 17491680; PMCID: PMC1783553.
Copy Download .nbib Format: NLM
[Gliptines: a new fashion?].

La Revue du praticien

Scheen AJ.
PMID: 23687746
Rev Prat. 2013 Mar;63(3):304-5.

No abstract available.

Cite
Scheen AJ. Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. Rev Prat. 2013;63(3):304-5
Scheen, A. J. (2013). Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. La Revue du praticien, 63(3), 304-5.
Scheen, André J. "Les gliptines, une nouvelle mode?" [Gliptines: a new fashion?]. La Revue du praticien vol. 63,3 (2013): 304-5.
Scheen AJ. Les gliptines, une nouvelle mode? [Gliptines: a new fashion?]. Rev Prat. 2013 Mar;63(3):304-5. French. PMID: 23687746.
Copy Download .nbib Format: NLM
Novel 8-heterocyclyl xanthine derivatives in drug development - an update.

Expert opinion on drug discovery

Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D.
PMID: 23496127
Expert Opin Drug Discov. 2007 Sep;2(9):1161-83. doi: 10.1517/17460441.2.9.1161.

Naturally occurring methyl xanthines, especially caffeine and theophylline, have been widely investigated for their pharmacological properties as cognition enhancers, bronchodilator agents and mild diuretics. The xanthine core (3,7-dihydro-1H-purine-2,6-dione) has been largely manipulated in the search for selective ligands for...

Cite
Baraldi PG, Fruttarolo F, Tabrizi MA, et al. Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert Opin Drug Discov. 2007;2(9):1161-83doi: 10.1517/17460441.2.9.1161.
Baraldi, P. G., Fruttarolo, F., Tabrizi, M. A., Romagnoli, R., & Preti, D. (2007). Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert opinion on drug discovery, 2(9), 1161-83. https://doi.org/10.1517/17460441.2.9.1161
Baraldi, Pier G, et al. "Novel 8-heterocyclyl xanthine derivatives in drug development - an update." Expert opinion on drug discovery vol. 2,9 (2007): 1161-83. doi: https://doi.org/10.1517/17460441.2.9.1161
Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D. Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert Opin Drug Discov. 2007 Sep;2(9):1161-83. doi: 10.1517/17460441.2.9.1161. PMID: 23496127.
Copy Download .nbib Format: NLM
Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis.

Endocrinology, diabetes & metabolism

Kamalinia S, Josse RG, Donio PJ, Leduc L, Shah BR, Tobe SW.
PMID: 31922027
Endocrinol Diabetes Metab. 2019 Nov 13;3(1):e00100. doi: 10.1002/edm2.100. eCollection 2020 Jan.

OBJECTIVES: For patients with type 2 diabetes, newer antihyperglycaemic agents (AHA), including the dipeptidyl peptidase IV inhibitors (DPP4i), glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium glucose co-transporter 2 inhibitors (SGLT2i) offer a lower risk of hypoglycaemia relative to sulfonylurea...

Cite
Kamalinia S, Josse RG, Donio PJ, et al. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. Endocrinol Diabetes Metab. 2019;3(1):e00100doi: 10.1002/edm2.100.
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2020). Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. Endocrinology, diabetes & metabolism, 3(1), e00100. https://doi.org/10.1002/edm2.100
Kamalinia, Sanaz, et al. "Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis." Endocrinology, diabetes & metabolism vol. 3,1 (2020): e00100. doi: https://doi.org/10.1002/edm2.100
Kamalinia S, Josse RG, Donio PJ, Leduc L, Shah BR, Tobe SW. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. Endocrinol Diabetes Metab. 2019 Nov 13;3(1):e00100. doi: 10.1002/edm2.100. eCollection 2020 Jan. PMID: 31922027; PMCID: PMC6947712.
Copy Download .nbib Format: NLM
Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis.

Diabetes/metabolism research and reviews

Overbeek JA, Bakker M, van der Heijden AAWA, van Herk-Sukel MPP, Herings RMC, Nijpels G.
PMID: 29573125
Diabetes Metab Res Rev. 2018 Jul;34(5):e3004. doi: 10.1002/dmrr.3004. Epub 2018 Apr 26.

The long-term impact of dipeptidyl peptidase-4 (DPP-4) inhibition is unknown, and there are concerns about the influence of DPP-4 inhibition on carcinogenesis of the pancreas and thyroid. As DPP-4 is a rather unselective enzyme present in many tissues, we...

Cite
Overbeek JA, Bakker M, van der Heijden AAWA, et al. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018;34(5):e3004doi: 10.1002/dmrr.3004.
Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk-Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018). Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes/metabolism research and reviews, 34(5), e3004. https://doi.org/10.1002/dmrr.3004
Overbeek, Jetty A, et al. "Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis." Diabetes/metabolism research and reviews vol. 34,5 (2018): e3004. doi: https://doi.org/10.1002/dmrr.3004
Overbeek JA, Bakker M, van der Heijden AAWA, van Herk-Sukel MPP, Herings RMC, Nijpels G. Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2018 Jul;34(5):e3004. doi: 10.1002/dmrr.3004. Epub 2018 Apr 26. PMID: 29573125.
Copy Download .nbib Format: NLM
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.

Journal of clinical medicine

Kim YG, Jeon JY, Kim HJ, Kim DJ, Lee KW, Moon SY, Han SJ.
PMID: 30597861
J Clin Med. 2018 Dec 28;8(1). doi: 10.3390/jcm8010028.

BACKGROUND: Type 2 diabetes is related to an increased risk of dementia. Preclinical studies of dipeptidyl peptidase-IV inhibitors (DPP-4i) for dementia have yielded promising results. Therefore, we investigated the risk of dementia in elderly patients with type 2 diabetes...

Cite
Kim YG, Jeon JY, Kim HJ, et al. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. J Clin Med. 2018;8(1)doi: 10.3390/jcm8010028.
Kim, Y. G., Jeon, J. Y., Kim, H. J., Kim, D. J., Lee, K. W., Moon, S. Y., & Han, S. J. (2018). Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. Journal of clinical medicine, 8(1), . https://doi.org/10.3390/jcm8010028
Kim, Young-Gun, et al. "Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study." Journal of clinical medicine vol. 8,1 (2018). doi: https://doi.org/10.3390/jcm8010028
Kim YG, Jeon JY, Kim HJ, Kim DJ, Lee KW, Moon SY, Han SJ. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. J Clin Med. 2018 Dec 28;8(1). doi: 10.3390/jcm8010028. PMID: 30597861; PMCID: PMC6352270.
Copy Download .nbib Format: NLM
Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.

Frontiers in endocrinology

Zhao D, Zhao S, Wang X, Su M, Liu W, Ma Q, Hong J, Gu W, Li J, Liu R, Ning G, Wang J, Zhang Y.
PMID: 29556215
Front Endocrinol (Lausanne). 2018 Mar 05;9:62. doi: 10.3389/fendo.2018.00062. eCollection 2018.

The clinical application of dipeptidyl peptidase IV inhibitors (DPP4i) increasing active glucagon-like peptide-1 (AGLP-1) levels has been linked to pancreatitis, pancreatic tumors, and cardiovascular events. However,

Cite
Zhao D, Zhao S, Wang X, et al. Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. Front Endocrinol (Lausanne). 2018;9:62doi: 10.3389/fendo.2018.00062.
Zhao, D., Zhao, S., Wang, X., Su, M., Liu, W., Ma, Q., Hong, J., Gu, W., Li, J., Liu, R., Ning, G., Wang, J., & Zhang, Y. (2018). Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. Frontiers in endocrinology, 962. https://doi.org/10.3389/fendo.2018.00062
Zhao, Dandan, et al. "Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier." Frontiers in endocrinology vol. 9 (2018): 62. doi: https://doi.org/10.3389/fendo.2018.00062
Zhao D, Zhao S, Wang X, Su M, Liu W, Ma Q, Hong J, Gu W, Li J, Liu R, Ning G, Wang J, Zhang Y. Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier. Front Endocrinol (Lausanne). 2018 Mar 05;9:62. doi: 10.3389/fendo.2018.00062. eCollection 2018. PMID: 29556215; PMCID: PMC5845420.
Copy Download .nbib Format: NLM
Preserving insulin secretion in Type 2 diabetes mellitus.

Expert review of endocrinology & metabolism

Tibaldi J.
PMID: 30764089
Expert Rev Endocrinol Metab. 2008 Mar;3(2):147-159. doi: 10.1586/17446651.3.2.147.

Type 2 diabetes mellitus (T2DM) is a complex disease characterized by insulin resistance and a progressive decline in β-cell function and mass. Current evidence suggests that β-cell dysfunction is present early in the course of the disease and that...

Cite
Tibaldi J. Preserving insulin secretion in Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2008;3(2):147-159doi: 10.1586/17446651.3.2.147.
Tibaldi, J. (2008). Preserving insulin secretion in Type 2 diabetes mellitus. Expert review of endocrinology & metabolism, 3(2), 147-159. https://doi.org/10.1586/17446651.3.2.147
Tibaldi, Joseph. "Preserving insulin secretion in Type 2 diabetes mellitus." Expert review of endocrinology & metabolism vol. 3,2 (2008): 147-159. doi: https://doi.org/10.1586/17446651.3.2.147
Tibaldi J. Preserving insulin secretion in Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2008 Mar;3(2):147-159. doi: 10.1586/17446651.3.2.147. PMID: 30764089.
Copy Download .nbib Format: NLM
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea.

Endocrinology and metabolism (Seoul, Korea)

Seo DH, Ha KH, Kim SH, Kim DJ.
PMID: 33677929
Endocrinol Metab (Seoul). 2021 Feb;36(1):70-80. doi: 10.3803/EnM.2020.777. Epub 2021 Feb 24.

BACKGROUND: Results regarding the cardiovascular (CV) effects of dipeptidyl peptidase-4 (DPP-4) inhibitors are inconsistent. This study aimed to assess the effects of teneligliptin, a DPP-4 inhibitor, on the risk of major CV outcomes in type 2 diabetes mellitus (T2DM)...

Cite
Seo DH, Ha KH, Kim SH, et al. Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea. Endocrinol Metab (Seoul). 2021;36(1):70-80doi: 10.3803/EnM.2020.777.
Seo, D. H., Ha, K. H., Kim, S. H., & Kim, D. J. (2021). Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea. Endocrinology and metabolism (Seoul, Korea), 36(1), 70-80. https://doi.org/10.3803/EnM.2020.777
Seo, Da Hea, et al. "Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea." Endocrinology and metabolism (Seoul, Korea) vol. 36,1 (2021): 70-80. doi: https://doi.org/10.3803/EnM.2020.777
Seo DH, Ha KH, Kim SH, Kim DJ. Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea. Endocrinol Metab (Seoul). 2021 Feb;36(1):70-80. doi: 10.3803/EnM.2020.777. Epub 2021 Feb 24. PMID: 33677929; PMCID: PMC7937854.
Copy Download .nbib Format: NLM
Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods.

Critical reviews in food science and nutrition

Jia Y, Cai S, Muhoza B, Qi B, Li Y.
PMID: 34652225
Crit Rev Food Sci Nutr. 2021 Oct 15;1-16. doi: 10.1080/10408398.2021.1989659. Epub 2021 Oct 15.

Dietary polyphenols with great antidiabetic effects are the most abundant components in edible products. Dietary polyphenols have attracted attention as dipeptidyl peptidase-IV (DPP-IV) inhibitors and indirectly improve insulin secretion. The DPP-IV inhibitory activities of dietary polyphenols depend on their...

Cite
Jia Y, Cai S, Muhoza B, et al. Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods. Crit Rev Food Sci Nutr. 2021;1-16doi: 10.1080/10408398.2021.1989659.
Jia, Y., Cai, S., Muhoza, B., Qi, B., & Li, Y. (2021). Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods. Critical reviews in food science and nutrition, 1-16. https://doi.org/10.1080/10408398.2021.1989659
Jia, Yijia, et al. "Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods." Critical reviews in food science and nutrition vol. (2021): 1-16. doi: https://doi.org/10.1080/10408398.2021.1989659
Jia Y, Cai S, Muhoza B, Qi B, Li Y. Advance in dietary polyphenols as dipeptidyl peptidase-IV inhibitors to alleviate type 2 diabetes mellitus: aspects from structure-activity relationship and characterization methods. Crit Rev Food Sci Nutr. 2021 Oct 15;1-16. doi: 10.1080/10408398.2021.1989659. Epub 2021 Oct 15. PMID: 34652225.
Copy Download .nbib Format: NLM
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.

Archives of dermatological research

Kridin K, Avni O, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD.
PMID: 35032198
Arch Dermatol Res. 2022 Jan 15; doi: 10.1007/s00403-021-02317-9. Epub 2022 Jan 15.

The timing pattern in which dipeptidyl-peptidase IV inhibitors (DPP4i) confer the risk of bullous pemphigoid (BP) is unknown. To investigate the odds of BP following exposure to DPP4i and to perform a duration-response analysis evaluating the risk of BP...

Cite
Kridin K, Avni O, Damiani G, et al. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation. Arch Dermatol Res. 2022;doi: 10.1007/s00403-021-02317-9.
Kridin, K., Avni, O., Damiani, G., Tzur Bitan, D., Onn, E., Weinstein, O., & Cohen, A. D. (2022). Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation. Archives of dermatological research, . https://doi.org/10.1007/s00403-021-02317-9
Kridin, Khalaf, et al. "Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation." Archives of dermatological research vol. (2022). doi: https://doi.org/10.1007/s00403-021-02317-9
Kridin K, Avni O, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD. Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation. Arch Dermatol Res. 2022 Jan 15; doi: 10.1007/s00403-021-02317-9. Epub 2022 Jan 15. PMID: 35032198.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 91 entries